Page 58 - Memora anual Fundación CIEN 2015

The Vallecas Project The phase of recruiting volunteers for participation in
the study was finished in December 31, 2013, with its
It is currently known that the pathological processes corresponding baseline assessment (n = 1,213). The
that determine Alzheimer begin many years before project includes activities from the Multidisciplinary
the disease leads to the first noticeable symptoms in Support Unit (UMA), Neuroimaging, and Laboratory.
patients. Years before that future drug treatments During 2015 we have studied 22 volunteers to com-
preventing or slowing down disease progression plete the second follow-up study, 245 volunteers on
could be applied to the "population at risk" who has the third visit, 445 on the fourth visit, and 5 from the
developed these subclinical lesions, or has an higher third visit.
risk of developing it than the rest of the population.
Of all patients recruited in the study and having an
In this context it is framed the Vallecas Project, which informed consent, a blood sample is collected and
is constituted as a 5-year longitudinal study specifi- immediately transferred to the laboratory for frac-
cally aimed at discovering the factors that would tionation into aliquots following the so-called Vienna
allow us to detect this "population at risk" in a phase Institute of Neurology protocol, which allow different
of potentially treatable pathology. types of analysis, as well as classification and sto-
rage (see Figure below). Additionally, one blood
Distribution of APOE genotypes tube (BD-CPT citrate Vacutainer) for the isolation of
in the CAFRS patients mononuclear leukocytes, together with another
cohort tube lacking anticoagulant to obtain serum are pro-
cessed.
Genotypes APOE ε2/ε4
2 Within the department of laboratory, the Vallecas
ε2/ε3 1% Project activity in figures is shown in the attached
ε2/ε2 9 table.

1 3% Primary aliquots in duplicate are collected for the fo-
ε4/ε4 0% llowing fractions:

21
8%

ε3/ε4 ε3/ε3 • Whole blood (ST, for its acronym in Spanish)
111 135 • Platelets-rich plasma (PRP)
40% 48% • Platelets-free plasma (PFP)
• Buffy Coat (BC)
• Red blood cells (RBC)
• Serum (Suero, in Spanish)
• Mononucleate leukocytes (LM, for its acronym in

Spanish)

Genomic DNA was extracted from whole blood of
all participants who have signed informed consent
to it and the APOE gene, an important marker of ge-
netic risk for Alzheimer's disease, was analyzed. The

CIEN Foundation Annual Report 2015 / 60